<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Toll-like receptors: Roles in disease and therapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Toll-like receptors: Roles in disease and therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Toll-like receptors: Roles in disease and therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas McDonald, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Toll-like receptors (TLRs) are cell surface and intracellular molecules on eukaryotic cells that detect and respond to microbial antigens. They derive their name from homology to the <em>Drosophila</em> Toll molecule, an important component of dorsal-ventral patterning and antifungal defense [<a href="#rid1">1,2</a>]. TLRs are part of the innate immune system, which is a phylogenetically ancient system present in invertebrates and conserved through vertebrate evolution. Innate immune responses are initiated rapidly by exposure to microbes and precede the development of adaptive immune responses [<a href="#rid3">3</a>]. Innate immunity is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/13572.html" rel="external">"An overview of the innate immune system"</a>.)</p><p class="headingAnchor" id="H3625244456"><span class="h1">ROLE IN INNATE IMMUNITY</span><span class="headingEndMark"> — </span>TLRs are a type of pattern recognition receptor (PRR), which are receptors specific for molecular components of micro-organisms that are not made by the host. The ligands for TLRs are called pathogen-associated molecular patterns (PAMPs), which are components of pathogenic microbes. In vertebrates, TLRs initiate protective functions that operate independently from adaptive immunity. They also play a critical role in adaptive immune responses by directing the differentiation of naïve T cells into effector T cells. Other examples of PRRs include nucleotide oligomerization domain (NOD)-like receptors (NLRs) and the retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs). (See  <a class="medical medical_review" href="/z/d/html/13572.html" rel="external">"An overview of the innate immune system", section on 'Pattern recognition receptors'</a>.)</p><p class="headingAnchor" id="H9261997"><span class="h1">STRUCTURE AND FUNCTION OF TLRs</span><span class="headingEndMark"> — </span>Different species have different numbers of distinct TLRs. At least 10 have been discovered in humans [<a href="#rid1">1,2,4</a>]. With the exception of TLR1, TLR2, and TLR6, TLRs initiate signaling by homodimerization (eg, two identical TLRs brought together). TLR2 forms heterodimers with TLR1 (TLR2/1) or TLR6 (TLR2/6). Receptor structure/organization, ligands, and signaling are summarized in the table  (<a class="graphic graphic_table graphicRef61291" href="/z/d/graphic/61291.html" rel="external">table 1</a>) and figure  (<a class="graphic graphic_figure graphicRef57602" href="/z/d/graphic/57602.html" rel="external">figure 1</a>).</p><p>The structure of all of the TLRs is similar. All have an extracellular ligand recognition and binding domain that contains leucine-rich repeats. All have a single transmembrane domain. The cytoplasmic (signaling) domain is homologous to the interleukin-1 (IL-1) receptor and is called a toll/IL-1 receptor or TIR domain.</p><p>The final common pathway for TLR signaling involves the transcription factors, nuclear factor (NF) for the kappa (k) light chain enhancer in B cells (NF-kB) and activating protein-1 (AP-1). These transcription factors regulate a multitude of genes, including those encoding important proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), IL-1-beta, IL-6, IL-8, and IL-12. Some TLRs also activate production of type 1 (alpha and beta) interferons by inducing the interferon regulatory factors (IRFs) IRF3, IRF5, and IRF7.</p><p class="headingAnchor" id="H3"><span class="h2">Cellular and tissue distribution</span><span class="headingEndMark"> — </span>TLRs are differentially expressed on various leukocyte populations [<a href="#rid2">2,5</a>]. Monocytes and macrophages express all TLRs, except TLR3. Myeloid dendritic cells (MDCs) express TLR2/1, TLR3, TLR4, TLR5, and TLR8, while plasmacytoid dendritic cells (PDCs) express TLR7 and TLR9. TLR2/6, TLR4, and TLR8 are found on mast cells. B cells express TLR3, TLR7, TLR9, and TLR10, while T cells express TLR3 and TLR9. A variety of tissue types may express one or more TLRs. As an example, the basolateral surfaces of intestinal epithelial cells express TLR5, whereas fibroblasts and keratinocytes express TLR3 on the cell surface [<a href="#rid6">6</a>].</p><p>The cellular localization of TLRs varies. TLR2/1, TLR2/6, TLR4, TLR5, TLR10, and TLR11 are localized to cell surfaces, whereas TLR3, TLR7, TLR8, and TLR9 are localized within endosomes. The cell surface expression of TLRs, such as TLR4, which recognizes lipopolysaccharide (LPS), is hypothesized to allow recognition of extracellular molecules released from pathogens. Endosomal expression of TLR3, TLR7, TLR8, and TLR9 allows recognition of microbial nucleic acids following their uptake and degradation in phagolysosomes. TLR3, TLR7, TLR8, and TLR9 interact with an endoplasmic reticulum (ER) membrane protein called UNC93B (UNC93 homolog B), which is essential for proper signaling [<a href="#rid7">7</a>]. Additionally, endosomal expression of TLR3, TLR7, TLR8, and TLR9 may prevent activation by host nucleic acids and the development of autoimmunity.</p><p class="headingAnchor" id="H4"><span class="h2">Signaling</span><span class="headingEndMark"> — </span>All TLRs, except TLR3, utilize the cytoplasmic proximal signaling intermediate myeloid differentiation primary response protein 88 (MyD88), either by itself (TLR5, TLR7, TLR8, and TLR9) or together with the adapter molecule toll/interleukin-1 (IL-1) receptor (TIR) domain-containing adapter protein (TIRAP/MyD88 adapter-like [MAL], TLR2/1, TLR2/6, and TLR4)  (<a class="graphic graphic_figure graphicRef57602" href="/z/d/graphic/57602.html" rel="external">figure 1</a>) [<a href="#rid1">1,2,8</a>]. There is also a MyD88-independent pathway via the molecule TIR domain-containing adapter-inducing interferon-beta (IFN-beta) (TRIF), which is used by TLR3 and TLR4 (TLR4 also utilizes the intermediate TRIF-related adapter molecule [TRAM]).</p><p>The MyD88 adapter connects through interleukin-1 (IL-1) receptor-associated kinases 1 and 4 (IRAK1, IRAK4), tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6), and transforming growth factor (TGF)-beta-activated protein kinase 1 (TAK1) to the mitogen-activated protein kinases (MAPKs). This complex kinase cascade culminates in activation of the family of heterodimeric transcription factors known as activating protein-1 (AP-1). These transcription factors regulate a broad array of genes influencing cell survival, activation, and proliferation.</p><p>The TAK1 adapter also leads to activation of the inhibitor of NF-kB kinase (IKK) and resultant activation of NF-kB. This is another family of heterodimeric transcription factors regulating many genes with important roles in immune responses, as well as in the physiology of a broad array of other cell types. These include cytokines, chemokines and growth factors, lymphocyte receptors, adhesion molecules, acute-phase reactants, and other transcription factors. Ligation of TLR3 leads to activation of TRAF3 followed by tank-binding kinase 1 (TBK1) and IKK, which in turn activate interferon regulatory factor 3 (IRF3), leading to production of type 1 interferons. TLR7, TLR8, and TLR9 signal via a MyD88-dependent pathway that utilizes IRAK1/4, IKK-alpha, TRAF3/6, and intracellular osteopontin (iOPN), which activates IRF7, leading to production of interferon-alpha (IFN-alpha) [<a href="#rid9">9</a>]. In addition, TLR7-induced production of IFN-alpha has been shown to be dependent upon activation of IRF5 [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Regulation</span><span class="headingEndMark"> — </span>Both the cell surface expression of TLRs and the intracellular consequences of TLR ligation are regulated by a variety of factors. These include exposure to microbial products, other TLR ligands, and cytokines. Suppressor of cytokine signaling (SOCS) proteins and ubiquitin-mediated degradation of signaling proteins are involved in negative regulation of TLR signaling [<a href="#rid11">11,12</a>]. Within the gastrointestinal tract, the factors that maintain tolerance to commensal host flora while detecting/containing pathogenic bacteria with appropriate inflammatory responses are incompletely understood. The detection of common PAMPs in pathogenic and nonpathogenic bacteria would be anticipated to activate the same inflammatory response. Nevertheless, the detection of commensal bacteria within the intestines can induce tolerance. TLR signaling can contribute to intestinal homeostasis by regulating intestinal epithelial cell proliferation and epithelial integrity [<a href="#rid13">13</a>]. Expression and localization of TLRs in the intestinal epithelium may directly relate to their role in maintaining homeostasis versus inducing inflammation. For example, within the intestinal epithelium, TLR9 activation through the apical membrane induces tolerance, whereas TLR9 activation via the basolateral membrane induces an inflammatory response through the canonical NF-kB pathway. Differential spatial expression of pattern recognition receptors (PRRs) in epithelia may constitute a critical mechanism of distinguishing nonpathologic from pathologic bacteria. Regulation of TLR function is highly complex and still incompletely understood and beyond the scope of this review [<a href="#rid14">14-17</a>].</p><p class="headingAnchor" id="H6"><span class="h1">SPECIFIC TLRs</span><span class="headingEndMark"> — </span>The ligands, cellular expression, signaling molecules utilized, and resultant cellular effects of ligation for each of the TLRs are summarized in the table  (<a class="graphic graphic_table graphicRef61291" href="/z/d/graphic/61291.html" rel="external">table 1</a>). Additional information is presented below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>TLR2/1</strong> – The heterodimer of TLR2 with TLR1 binds to cell wall components of bacteria and mycobacteria. TLR2/1 binds triacyl lipopeptides/lipoproteins and some diacyl lipopeptides [<a href="#rid18">18-20</a>]. It also interacts with porins of <em>Neisseria</em> [<a href="#rid21">21</a>]. TLR2/1 is expressed on myeloid dendritic cells (MDCs) and signals via the canonical myeloid differentiation primary response protein 88 (MyD88) pathway with the toll/interleukin-1 (IL-1) receptor (TIR) domain-containing adapter protein (TIRAP). TLR2/1 also exists in a soluble form that can inhibit signaling via the membrane-bound receptor [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TLR2/6</strong> – The heterodimer of TLR2 with TLR6 displays a preference for recognizing diacyl lipopeptides, although it can recognize some triacyl lipopeptides [<a href="#rid18">18-20</a>]. TLR2/6 is expressed on mast cells, and it also signals via the canonical MyD88 pathway with the TIRAP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TLR3</strong> – TLR3 binds double-stranded RNA (dsRNA), which is produced in the replication of many viruses [<a href="#rid23">23</a>]. TLR3 may also bind to synthetic dsRNA, such as polyinosinic-polycytidylic acid (polyI:C) [<a href="#rid24">24</a>]. TLR3 is found within endolysosomes (membrane-bound intracellular compartments formed by the fusion of vesicles of internalized viral debris and lysosomes containing degradative enzymes) of MDCs, B cells, T cells, and natural killer (NK) cells [<a href="#rid25">25</a>]. TLR3 signals via a MyD88-independent pathway (TIR domain-containing adaptor-inducing interferon [TRIF]) and induces production of type 1 interferon-beta (IFN-beta) in addition to inflammatory cytokines.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TLR4</strong> – The principal ligand for TLR4 is the lipopolysaccharide (LPS) of Gram-negative bacteria [<a href="#rid26">26</a>]. The interaction of LPS with TLR4 occurs in a complex with LPS-binding protein (LBP), CD14, and a molecule called myeloid differentiation factor-2 (MD-2)  (<a class="graphic graphic_figure graphicRef57602" href="/z/d/graphic/57602.html" rel="external">figure 1</a>). Additional ligands include the fusion protein of respiratory syncytial virus (RSV), heat shock proteins of organisms, such as <em>Chlamydia pneumoniae</em>, and components of the extracellular matrix, such as fibronectin, hyaluronic acid, and heparan sulfate [<a href="#rid27">27-29</a>]. TLR4 is expressed on MDCs and mast cells and can signal via MyD88 with TIRAP. It may also induce type 1 IFN through the MyD88-independent pathway via TRIF-related adaptor molecule (TRAM).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TLR5</strong> – TLR5 recognizes bacterial flagellin [<a href="#rid30">30</a>]. It is expressed on MDCs and transduces signals via MyD88.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TLR7 and TLR8</strong> – TLR7 and TLR8 are very similar in their ligand binding and signaling [<a href="#rid31">31-33</a>]. Both bind to single-stranded RNA (ssRNA) from viruses, such as influenza and human immunodeficiency virus-I (HIV-I). They also recognize imidazoquinolines (synthetic heterocyclic organic molecules), such as <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a>, and guanosine analogs, such as loxoribine. TLR7 is expressed on MDCs, plasmacytoid dendritic cells (PDCs), and B lymphocytes. TLR8 is expressed on MDCs and mast cells. Both signal directly via MyD88.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TLR9</strong> – TLR9 interacts with unmethylated cytosine guanine dinucleotide (CpG) motifs in microbial DNA [<a href="#rid34">34</a>]. TLR9 is expressed within endolysosomes of PDCs, B cells, and T cells and signals directly via MyD88. Activation of PDCs (also known as IFN-producing cells) through TLR7 and TLR9 leads to production of large quantities of IFN-alpha, which plays a critical role in antiviral innate immunity. Additionally, PDCs, by virtue of their production of IFN-alpha and IL-12, are potent inducers of differentiation of naïve T cells into T helper type 1 (Th1) effector T cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TLR10</strong> – TLR10 is a modulatory PRR with largely inhibitory functions [<a href="#rid35">35,36</a>]. TLR10 is believed to exert inhibitory functions through competition with ligand binding to TLRs. Furthermore, TLR10 may compete for heterodimer formation with TLR2. TLR10 activation also leads to increased expression of IL-1 receptor antagonist (IL-1RA), which decreases inflammation. Recently, TLR10 was found to be a receptor for HIV gp41 binding, leading to activation of NF-kB and IL-8 production in macrophages, monocytes, and mammary epithelial cells, suggesting it may be an innate sensor of HIV infection. Binding of HIV gp41 to TLR10 leads to upregulation of expression of TLR10. However, increased expression of TLR10 may result in enhanced HIV infection by allowing entry into monocytes, macrophages, and epithelial cells [<a href="#rid37">37</a>].</p><p></p><p class="headingAnchor" id="H15"><span class="h1">CELLULAR RESPONSES INDUCED BY TLRs</span><span class="headingEndMark"> — </span>The response to various combinations of TLRs depends on the cell expressing that TLR, the relative amounts and types of TLRs present, as well as other stimuli and the developmental program of the target cell.</p><p class="bulletIndent1"><span class="glyph">●</span>TLR ligation of mononuclear cells may potentiate the microbicidal activity of phagocytic cells. As an example, TLR2/1 or TLR2/6 ligation by cell wall components of <em>Mycobacterium tuberculosis</em> induces nitric oxide production in mice and other bactericidal mechanisms in humans [<a href="#rid38">38</a>]. The same ligand/receptor combination may also lead to apoptosis in macrophages [<a href="#rid39">39</a>]. This mechanism could potentially limit the spread of microbes that are replicating intracellularly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TLR activation of epithelial cells can induce production of antimicrobial peptides (defensins) that provide protection against a wide variety of pathogens. TLR activation in intestinal epithelial cells can contribute to intestinal homeostasis by regulating intestinal cell proliferation and epithelial integrity. Depending on the cellular localization of TLRs in intestinal epithelia (ie, apical membrane), TLR activation may induce tolerance, whereas activation of TLRs within the basolateral membrane induces an inflammatory response to invasive bacteria [<a href="#rid40">40-42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activation of TLRs on dendritic cells leads to antigen presentation, production of IL-12, and upregulation of costimulatory molecules (CD80, CD86), which directs the differentiation of naïve T cells into antigen-specific Th1 effector T cells [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TLR activation (TLR3, TLR7, TLR8, TLR9) results in production of type 1 interferons, which plays a crucial role in antiviral innate immunity. Different TLR ligands may lead to somewhat different cytokine responses or may induce type 1 interferon and lead to activation of qualitatively different types of immune responses (eg, T helper type 1 [Th1] versus T helper type 2 [Th2] T cell differentiation) [<a href="#rid2">2</a>]. The response to various combinations of TLRs also depends on the relative amounts and types of TLRs on the cell surface, as well as other stimuli and the developmental program of the target cell.</p><p></p><p class="bulletIndent1">Because pathogens coevolved with their hosts, we (the host) have acquired sophisticated mechanisms for resisting infection, including TLRs. In turn, pathogens have developed strategies to circumvent many of these mechanisms. For example, vaccinia virus encodes molecules with homology to toll/interleukin-1 (IL-1) receptor (TIR) domains and can inhibit signaling via TLR3 and TLR4 [<a href="#rid44">44,45</a>].</p><p></p><p class="headingAnchor" id="H3385581618"><span class="h1">TLR SIGNALING DEFECTS IN PRIMARY IMMUNODEFICIENCY</span><span class="headingEndMark"> — </span>Defects have been identified in molecules that transduce signals from TLRs and lead to primary immunodeficiency  (<a class="graphic graphic_table graphicRef112782" href="/z/d/graphic/112782.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H588040242"><span class="h2">Specific disorders</span><span class="headingEndMark"> — </span>The degree of immunologic impairment is related to where in the TLR signaling pathway the defect occurs  (<a class="graphic graphic_figure graphicRef112546" href="/z/d/graphic/112546.html" rel="external">figure 2</a>). Defects that occur proximally in the TLR pathway, such as deficiency in myeloid differentiation primary response protein 88 (MyD88) or interleukin-1 (IL-1) receptor-associated kinase 4 (IRAK4) lead to susceptibility to a limited number of pathogens (typically pyogenic bacteria), since these defects only impair the function of TLRs and IL-1R.</p><p>In contrast, distal defects involving transcription factors (ie, nuclear factor [NF]-kB complex) lead to broader infectious susceptibilities (eg, bacteria, viruses, fungi, and opportunistic organisms), as well as developmental abnormalities (ie, ectodermal dysplasia). This is because of the diverse immune and developmental mechanisms that signal through NF-kB, including pathways in innate immunity (ie, TLRs), adaptive immunity (ie, T cell receptor, B cell receptor, and CD40), and ectodermal development (ie, ectodysplasin A receptor).</p><p class="headingAnchor" id="H5549320"><span class="h3">MyD88/IRAK4/IRAK1 deficiency</span><span class="headingEndMark"> — </span>All TLRs, except TLR3, use the cytoplasmic proximal signaling intermediate myeloid differentiation primary response protein 88 (MyD88), either by itself or together with the adapter molecule toll/IL-1 receptor domain-containing adapter protein (TIRAP). MyD88 deficiency was initially described in nine children suffering from recurrent and severe pyogenic bacterial infections [<a href="#rid46">46</a>]. These children were susceptible to invasive infections with <em>Streptococcus pneumoniae</em>, <em>Staphylococcus aureus</em>, and <em>Pseudomonas aeruginosa</em>, but had normal resistance to other common bacteria, viruses, fungi, and parasites. Three children died before the age of 1 year, while another six were alive at ages 3 to 16 years at the time of publication. Susceptibility to infection improved with age in affected patients, although MyD88 levels did not change, suggesting that maturation of the adaptive immune system may compensate for defective TLR function. The defect displayed autosomal recessive inheritance. MyD88 deficiency is clinically indistinguishable from IL-1 receptor-associated kinase 4 (IRAK4) deficiency, since IRAK4 associates with MyD88 in signal transduction [<a href="#rid47">47</a>].</p><p>Deficiency of IRAK4 (MIM 607676) impairs signaling from the TLRs that associate only with the MyD88 adapter  (<a class="graphic graphic_figure graphicRef112557" href="/z/d/graphic/112557.html" rel="external">figure 3</a>). These include TLR2/1, TLR2/6, TLR5, TLR7, TLR8, and TLR9. TLR4 signals through MyD88, but can also make use of the toll/IL-1 receptor (TIR) domain-containing adapter-inducing interferon-beta (IFN-beta) (TRIF)-related adapter molecule (TRAM)/TRIF pathway. TLR3 is unaffected. Signaling by the IL-1 receptor and T cell receptor activation are also impaired [<a href="#rid48">48</a>]. Peripheral blood mononuclear cells from patients with IRAK4 deficiency or MyD88 deficiency do not produce proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha), IL-1, and IL-6 when stimulated via IL-1 or IL-18 receptors or TLRs. The lack of responsiveness to IL-1 results in impaired fever responses to bacterial infection. The lack of significant fever and the unexpectedly low level of C-reactive protein (CRP) in the setting of a serious bacterial infection can be a clue to the possibility of IRAK4 deficiency or MyD88 deficiency.</p><p>The clinical and laboratory features of IRAK4 deficiency are indistinguishable from MyD88 deficiency, since IRAK4 associates with MyD88 in signal transduction  (<a class="graphic graphic_figure graphicRef112557" href="/z/d/graphic/112557.html" rel="external">figure 3</a>). Patients with IRAK4 deficiency have recurrent severe infections (cellulitis, arthritis, meningitis, osteomyelitis, organ abscesses, and sepsis), mainly caused by <em>S. aureus</em>, <em>S. pneumoniae</em>, and <em>P. aeruginosa</em> [<a href="#rid47">47,49,50</a>]. One series described 48 patients who experienced recurrent bacterial infections, mostly of the upper respiratory tract and skin [<a href="#rid51">51</a>]. None had severe viral, fungal, or parasitic infections. Initial invasive infections occurred before the age of two years in 88 percent. Invasive pneumococcal infections caused the most morbidity and mortality and were the cause of death in 33 percent. In patients with either IRAK4 deficiency or MyD88 defects, susceptibility to infections seems to improve with age, regardless of therapy [<a href="#rid47">47,52</a>]. In the largest series, no infectious deaths were reported in patients over the age of 8 years and no invasive infections after the age of 14 years [<a href="#rid47">47</a>].</p><p>Serum immunoglobulins are normal, specific antibody levels against polysaccharide antigens may be low or normal, and B cell subsets and function in vitro are normal. T cell responses to mitogens and recall antigens are also normal. Peripheral eosinophilia and elevated serum immunoglobulin E (IgE) may be observed.</p><p>The diagnosis can be made by measuring cytokine production by leukocytes that have been activated by various TLR ligands (TLR function assay, available in at least one commercial laboratory) [<a href="#rid53">53</a>]. Absence of functional MyD88 or IRAK4 results in an absence of proinflammatory production in affected patients. The absence of TLR-induced cytokine production in these patients must be then followed by gene sequencing to identify the precise genetic defect. Targeted gene panels are now commercially available and are cost effective.</p><p>Meticulous skin care to minimize bacterial colonization of the skin is also an essential element of patient management, since these patients remain susceptible to skin infections. Antibiotic or other therapy is dictated by specific pathogen sensitivity and the focus of infection. Antibiotic prophylaxis and/or <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> replacement therapy may be considered. Most MyD88- or IRAK4-deficient patients are maintained on antibiotic prophylaxis with <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> or sulfamethoxazole-trimethoprim indefinitely. </p><p>For the roughly 50 percent of MyD88- or IRAK4-deficient patients that do not have adequate antibody responses to polysaccharide pneumococcal vaccine (ie, Pneumovax), <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> replacement therapy is helpful, at least until adolescence when invasive infection risks diminish [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity"</a>.)</p><p>IRAK1 deficiency in a male due to a 112kb deletion, which deleted both MECP2 and IRAK1 on the X chromosome, has been reported [<a href="#rid54">54</a>]. Unfortunately, no information on the infectious consequences of the loss of IRAK1 is available because the patient died of progressive neurologic and respiratory insufficiency, presumably from absence of MECP2. Analysis of transformed fibroblasts from this patient demonstrated absent responses to stimulation of TLR ligands, whereas signaling downstream of IL-1R was relatively unimpaired, suggesting that IRAK1 plays an essential role in signaling downstream of TLRs but a redundant role downstream of IL-1R in fibroblasts. In contrast, TLR signaling in the patient's peripheral blood mononuclear cells was unimpaired, indicating that IRAK1 plays a redundant role that may be compensated by IRAK2.</p><p class="headingAnchor" id="H5549596"><span class="h3">UNC93B1 deficiency, TLR3 mutations, TRIF deficiency, TRAF3 deficiency, and TBK1 deficiency</span><span class="headingEndMark"> — </span>UNC93B1 (UNC93 homolog B1) is an endoplasmic reticulum (ER) protein that is involved in the transport of the nucleotide-sensing TLR7 and TLR9 from the ER to endolysosomes. Signaling through TLR3, TLR7, TLR8, and TLR9 normally induces production of type 1 interferons following binding to viral RNA  (<a class="graphic graphic_figure graphicRef112557" href="/z/d/graphic/112557.html" rel="external">figure 3</a>). Type 1 interferons are critical to controlling certain viruses during the earliest stages of infections.</p><p class="headingAnchor" id="H915593135"><span class="h4">HSV-1 encephalitis</span><span class="headingEndMark"> — </span>Deficiency of UNC93B1 or TLR3 (MIM 610551 and MIM 613002) leads to susceptibility to herpes simplex virus type 1 (HSV-1) encephalitis due to decreased production of interferons in the central nervous system [<a href="#rid55">55-58</a>]. Both autosomal dominant and autosomal recessive forms of toll/interleukin-1 (IL-1) receptor domain-containing adaptor-inducing interferon (TRIF) deficiency have been shown to cause susceptibility to HSV-1 encephalitis [<a href="#rid59">59</a>]. Autosomal dominant deficiency of tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3), which leads to reduced but not absent TRAF3 function, is another cause of susceptibility to HSV-1 encephalitis [<a href="#rid60">60</a>]. Finally, heterozygous mutations in tank-binding kinase 1 (TBK1) also result in susceptibility to HSV-1 encephalitis [<a href="#rid61">61</a>]. This group of patients with defective TLR3 signaling demonstrates the essential role of TLR3 in the central nervous system in the prevention of HSV-1 encephalitis. (See  <a class="medical medical_review" href="/z/d/html/8278.html" rel="external">"Herpes simplex virus type 1 encephalitis", section on 'Host susceptibility'</a>.)</p><p class="headingAnchor" id="H2058971776"><span class="h4">Severe influenza</span><span class="headingEndMark"> — </span>Deficiencies in TLR3, interferon regulatory factor 7 (IRF7), and IRF9 have been identified in children with life-threatening influenza pneumonia [<a href="#rid62">62-64</a>]. Additionally, a heterozygous missense mutation in TLR3 (F303S) was associated with influenza-associated encephalopathy, likely due to haploinsufficiency of TLR3 function [<a href="#rid65">65</a>]. </p><p class="headingAnchor" id="H1679467481"><span class="h4">Severe COVID-19</span><span class="headingEndMark"> — </span>Type 1 interferon production plays an essential role in host defense against coronaviruses. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is an RNA virus that is likely detected intracellularly by TLR3, 7, and 8, as well as RIG-I and MDA5. SARS-CoV-2 encodes numerous genes that can inhibit type 1 interferon production by blocking innate sensing (nsp16, 14), interferon production (M protein, N protein, nsp3, ORF 3b,4a, 4b, 5, 6), and interferon signaling (nsp1, ORF4b, 6), which contributes greatly to its virulence. Defects in genes involved type 1 interferon production, including TLR3, IRF7, UNC93B1, TICAM1, TBK1, and interferon alpha and beta receptor subunit 1 (IFNAR1) were found in 3.5 percent of patients hospitalized with life-threatening COVID-19  (<a class="graphic graphic_figure graphicRef112557" href="/z/d/graphic/112557.html" rel="external">figure 3</a>) [<a href="#rid66">66</a>]. Ten of 23 patient for whom blood samples were available from early in their hospitalization showed very low IFN-alpha levels compared with other patients with milder COVID-19 disease. In a parallel study by the same group, the presence of autoantibodies against specific type 1 interferons, which resulted in undetectable serum levels, were found in 10.2 percent of patients with life-threatening COVID-19 pneumonia compared with 0.33 percent of healthy individuals [<a href="#rid67">67</a>]. Thus, defects in the pathways generating type 1 interferons, inhibition of type 1 interferon production, and autoantibodies that neutralize interferons predispose to severe COVID-19.</p><p class="headingAnchor" id="H23"><span class="h3">NEMO defects</span><span class="headingEndMark"> — </span>NF-kB essential modifier (NEMO), also called the inhibitor of NF-kB kinase (IKK)-gamma, is encoded by a gene on the X chromosome (<em>IKBKG</em>). NEMO is required for the proper function of IKK, which inactivates the inhibitor of NF-kB (I-kappa [k]-B) proteins  (<a class="graphic graphic_figure graphicRef112557" href="/z/d/graphic/112557.html" rel="external">figure 3</a>). In the absence of IKK activity, I-kB remains bound to NF-kB, holding it in the cytoplasm in an inactive form and preventing its translocation to the nucleus to exert its transcriptional regulatory activities. Thus, in the absence of NEMO function, NF-kB signaling is blocked, shutting down many pathways, including innate immune functions (ie, TLRs, nucleotide-binding oligomerization domain [NOD]-like receptors [NLRs], retinoic acid-inducible gene-I [RIG-I]-like receptors [RLRs]), adaptive immune functions (T cell receptor, B cell receptor, CD40), and developmental pathways (ie, ectodysplasin A receptor in ectoderm and receptor activator of NF-kB [RANK] in osteoclasts)  (<a class="graphic graphic_figure graphicRef112546" href="/z/d/graphic/112546.html" rel="external">figure 2</a>). Complete absence of NEMO function is lethal in male embryos, and partial deficiency in females leads to a condition called incontinentia pigmenti [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/15513.html" rel="external">"Incontinentia pigmenti"</a>.)</p><p>Mutations that permit partial function of NEMO (ie, hypomorphic mutations) cause immunodeficiency of varying severity in males, ranging from recurrent sinopulmonary infections to extreme susceptibility to all classes of pathogens, including mycobacteria and opportunistic organisms. Because NF-kB also transduces signals from receptor systems important for the development of skin and skin appendages, the majority of patients with hypomorphic mutations also have ectodermal dysplasia, a disorder known as ectodermal dysplasia with immunodeficiency (ED-ID)  (<a class="graphic graphic_figure graphicRef112546" href="/z/d/graphic/112546.html" rel="external">figure 2</a>), although it can be present in very subtle ways in some patients. Ectodermal dysplasia is characterized by conical or absent teeth; fine, sparse hair; and hypohidrosis due to decreased sweat glands. NEMO mutations are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects", section on 'NEMO deficiency'</a>.)</p><p class="headingAnchor" id="H24"><span class="h3">I-kappa-B defects</span><span class="headingEndMark"> — </span>Multiple patients have been found to have mutations in the alpha subunit of the I-kB complex, an autosomal dominant form of ED-ID  (<a class="graphic graphic_figure graphicRef112557" href="/z/d/graphic/112557.html" rel="external">figure 3</a>). The phenotype is very similar to NEMO deficiency, leading to variable susceptibilities to infectious agents with (or without) ectodermal dysplasia. Testing of TLR function in patients suspected of having impaired NF-kB function can be informative. The degree of impairment in TLR function can range from insignificant to severely impaired, depending on the mutation in IKBKG or NFKBIA [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/3935.html" rel="external">"Combined immunodeficiencies: An overview"</a>.)</p><p class="headingAnchor" id="H1995217385"><span class="h3">DOCK8 deficiency</span><span class="headingEndMark"> — </span>Dedicator of cytokinesis 8 (DOCK8) deficiency is a combined immunodeficiency characterized by markedly elevated levels of immunoglobulin E (IgE), hypereosinophilia, atopic disorders, recurrent sinopulmonary infections, cutaneous candidiasis, and viral infections of the skin [<a href="#rid69">69</a>]. These patients have T cell lymphopenia and impaired serologic memory. DOCK8 is a guanine nucleotide exchange factor and an adapter protein important in TLR9 signaling and T cell receptor-driven Wiskott-Aldrich syndrome protein (WASp) activation and cytoskeleton reorganization [<a href="#rid70">70</a>]. DOCK8 deficiency results in impaired TLR9-induced B cell proliferation and immunoglobulin production, leading to poorly sustained protective antibody responses  (<a class="graphic graphic_figure graphicRef112547" href="/z/d/graphic/112547.html" rel="external">figure 4</a>). Patients also have a significant reduction in the number of circulating plasmacytoid dendritic cells (PDCs). The PDCs of DOCK8-deficient patients appear to produce less IFN-alpha in response to TLR9 activation, perhaps contributing to their susceptibility to viral infections [<a href="#rid71">71,72</a>]. (See  <a class="medical medical_review" href="/z/d/html/141326.html" rel="external">"Combined immunodeficiencies: Specific defects", section on 'DOCK8 deficiency'</a>.)</p><p class="headingAnchor" id="H928778308"><span class="h3">HOIL-1/HOIP deficiency</span><span class="headingEndMark"> — </span>Heme-oxidized IRP2 ubiquitin ligase-1 (HOIL-1) is a component of the linear ubiquitination chain assembly complex (LUBAC) that is essential for stabilization of the LUBAC and NF-kB activation downstream of the IL-1 receptor. HOIL-1 deficiency is an autosomal recessive disorder that causes impaired IL-1 activation of NF-kB in patient fibroblasts. Conversely, monocytes from these patients are hyper-responsive to IL-1  (<a class="graphic graphic_figure graphicRef112550" href="/z/d/graphic/112550.html" rel="external">figure 5</a>). This condition results in a unique association of immunodeficiency, autoinflammation, periodic fever, and muscular amylopectinosis. Homozygous mutations in HOIL-1 interacting protein (<em>HOIP)</em>, the gene encoding the catalytic component of LUBAC, leads to similar cellular impairments and a clinical condition nearly identical to HOIL-1 deficiency [<a href="#rid73">73,74</a>]. (See  <a class="medical medical_review" href="/z/d/html/122508.html" rel="external">"Autoinflammatory diseases mediated by NFkB and/or aberrant TNF activity", section on 'LUBAC deficiency'</a>.)</p><p class="headingAnchor" id="H25"><span class="h3">Common variable immunodeficiency</span><span class="headingEndMark"> — </span>Defects in the functioning of TLR7 and TLR9, normally prominent on B cells and dendritic cells, have been identified in patients with common variable immunodeficiency. These findings may be important in ultimately understanding the impaired B cell maturation that characterizes this disorder. TLR9-induced activation of STAT3 in B cells plays an important role in B cell maturation into memory B cells. A recent report that examined seven patients with CVID demonstrated reduced TLR9-induced activation of STAT3, which may underlie impaired antibody responses in some CVID patients [<a href="#rid75">75-77</a>]. (See  <a class="medical medical_review" href="/z/d/html/3904.html" rel="external">"Pathogenesis of common variable immunodeficiency"</a>.)</p><p>Heterozygous mutations in NF-kB1 (also known as p105/p50), leading to haploinsufficiency of NF-kB1 function and impaired activation of the canonical NF-kB pathway, have been shown to cause common variable immunodeficiency and hypogammaglobulinemia [<a href="#rid78">78,79</a>]. These patients suffered from recurrent sinopulmonary infections, chronic obstructive pulmonary disease (COPD), bronchiectasis, lymphadenopathy, skin infections, autoimmune cytopenias, inflammatory bowel disease, carcinomas, and adenocarcinomas. In addition, heterozygous mutations in NF-kB2 (also known as p100/p52), causing haploinsufficiency of NF-kB2 function and impaired activation of the noncanonical NF-kB pathway, lead to hypogammaglobulinemia, recurrent infections, autoimmunity, and adrenal insufficiency. Defective activation of TLRs has not been described in NF-kB1 or NF-kB2 haploinsufficiency  (<a class="graphic graphic_figure graphicRef112546" href="/z/d/graphic/112546.html" rel="external">figure 2</a>).</p><p class="headingAnchor" id="H1065914497"><span class="h2">When to suspect</span><span class="headingEndMark"> — </span>Immunodeficiencies resulting from defects with TLR pathways are extremely rare. The clinical scenarios in which a TLR pathway defect should be considered include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>An infant or child who develops invasive pyogenic infections (meningitis, adenitis, abscesses) caused by <em>S. pneumoniae</em>, <em>S. aureus</em>, or <em>P. aeruginosa</em>, particularly if there is minimal or no fever or an unexpectedly small rise in CRP. IRAK4 or MyD88 deficiency should be considered in this situation, after more common forms of immunodeficiency have been excluded  (<a class="graphic graphic_figure graphicRef112546" href="/z/d/graphic/112546.html" rel="external">figure 2</a>). (See <a class="local">'MyD88/IRAK4/IRAK1 deficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient with HSV-1 encephalitis could have a defect within the TLR3 pathway, although assessment of TLR function is not helpful, because TLR function is usually normal in blood cells and evaluation of fibroblasts is required. Instead, gene sequencing through targeted gene panels or whole exome sequencing may be the most efficient approach. (See <a class="local">'UNC93B1 deficiency, TLR3 mutations, TRIF deficiency, TRAF3 deficiency, and TBK1 deficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient with ectodermal dysplasia and recurrent infections (bacterial, viral, or mycobacterial) most likely has a mutation within NEMO or I-kB-alpha, as this combination of findings is relatively specific for these immunodeficiencies. However, not all patients with mutations in these proteins have ectodermal dysplasia. TLR-induced proinflammatory cytokine production has been shown to be variably reduced in many but not all affected individuals. Genetic detection of NEMO mutations can be confounded by the presence of a pseudogene. Genetic analysis can be obtained through commercial laboratories [<a href="#rid80">80</a>]. (See <a class="local">'NEMO defects'</a> above and <a class="local">'I-kappa-B defects'</a> above.)</p><p></p><p class="headingAnchor" id="H340285957"><span class="h3">Initial evaluation</span><span class="headingEndMark"> — </span>The initial evaluation of all patients suffering from recurrent infections begins with a detailed history of past infections, including frequency and severity, the specific sites of infections, and review of any available culture data to identify causative organisms. Because many immunodeficiencies are recessive traits, the clinician must ask about consanguinity within the family, although a lack of consanguinity does not rule out the possibility of compound heterozygous mutations. A family history of recurrent infection only affecting males focuses the evaluation on X-linked disorders.</p><p>Physical exam findings can provide important clues to possible immune disorders (eg, lack of tonsils in X-linked agammaglobulinemia or ectodermal dysplasia in NEMO/I-kB-alpha defects).</p><p>Laboratory evaluation should start with a complete blood count and differential to assess numbers of neutrophils and lymphocytes. Immunoglobulin levels should be measured, along with an assessment of specific antibody production (tetanus and pneumococcal titers). Immunophenotyping of lymphocytes, including assessment of memory T lymphocyte and memory B lymphocyte populations should be performed, along with T lymphocyte proliferation in response to mitogens and antigens. Immunologic testing is reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/3903.html" rel="external">"Laboratory evaluation of the immune system"</a>.)</p><p>If these evaluations fail to identify a potential immunodeficiency, further specialized testing is indicated.</p><p class="headingAnchor" id="H3836021400"><span class="h3">Referral and testing for TLR function</span><span class="headingEndMark"> — </span>Additional testing is best performed by an experienced immunologist who is familiar with this rare group of immunodeficiencies. Testing of TLR function is available through commercial reference laboratories [<a href="#rid81">81,82</a>]. A variety of in vitro methods may be applied. Most measure inflammatory cytokine production (eg, IL-6, IL-1, or tumor necrosis factor [TNF]) after stimulation with one or more TLR ligands (eg, bacterial lipopolysaccharide [LPS], an agonist of TLR4) [<a href="#rid83">83</a>].</p><p>Tests of TLR function are very sensitive to the condition of the cells. Blood should be sent as soon as possible after collection, especially if it is to be shipped a long distance (ship at ambient temperature, protect from heat or cold). If possible, the patient should be clinically well for at least a few weeks prior to testing and not actively recovering from any serious illness. A shipping control from an unrelated healthy donor should accompany the specimen. Abnormal tests need to be confirmed by repeat testing. Persistently abnormal tests should be followed up by specific genetic tests.</p><p class="headingAnchor" id="H431566095"><span class="h2">Significance of TLR polymorphisms</span><span class="headingEndMark"> — </span>A rapidly expanding area of research is the epidemiologic study of the many single nucleotide polymorphisms (SNPs) that have been identified in various TLR genes. Some early reports stated that certain variants of TLR2 and TLR4 were associated with impaired signaling after binding their natural ligands [<a href="#rid84">84,85</a>]. SNPs in TLR1 have been associated with candidemia, and SNPS in TLR4 have been associated with invasive aspergillosis among recipients of hematopoietic cell transplants [<a href="#rid86">86,87</a>]. (See  <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis", section on 'Risk factors'</a>.)</p><p>However, subsequent reports have challenged these findings and have stated that some of these polymorphisms do not have functional consequences [<a href="#rid83">83,88,89</a>]. It is not clear which is correct. Perhaps the answer depends on the specific stimulus, the response that is measured, or other variables.</p><p class="headingAnchor" id="H700364028"><span class="h1">ASSOCIATIONS BETWEEN TLRs AND OTHER DISEASES</span></p><p class="headingAnchor" id="H1656885411"><span class="h2">Atherosclerosis</span><span class="headingEndMark"> — </span>A large body of evidence has accumulated that various infectious agents have epidemiologic links with atherosclerotic heart disease [<a href="#rid90">90</a>]. These include <em>Chlamydia pneumoniae</em>, <em>Helicobacter pylori</em>, cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus type 1 (HSV-1), and hepatitis B and C [<a href="#rid91">91</a>]. Chronic infection and serum lipopolysaccharide (LPS) level have been identified as risk factors in a prospective study of the development of atherosclerotic heart disease [<a href="#rid92">92</a>].</p><p>Human atherosclerotic plaques contain endothelial cells and macrophages expressing TLR1/2 and TLR4 [<a href="#rid93">93</a>]. Minimally modified low density lipoprotein is an agonist of TLR4 [<a href="#rid94">94</a>]. It binds independently of CD14 and myeloid differentiation factor-2 (MD-2) and can induce production of chemokines, such as interleukin-8 (IL-8). Animal data strongly suggest roles for TLRs (particularly TLR4) in recognizing foreign (microbial) and self (extracellular matrix, heat shock proteins) molecules, activating endothelial cells, and recruiting and activating monocytes and macrophages to form inflammatory foci that could lead to the formation of atheromatous plaques [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H3753986115"><span class="h2">Allergy and asthma</span><span class="headingEndMark"> — </span>Most studies have found that exposure to bacterial products has been associated with protection from the development of allergic disease, and TLRs may be integral to the mechanisms involved. However, subsequent work suggests that this relationship may not be so straightforward.</p><p class="bulletIndent1"><span class="glyph">●</span>An association between exposure to endotoxin, which forms complexes with TLR4, and protection from allergic sensitization was found in multiple studies. As an example, a report of 61 wheezing infants recorded significantly lower levels of endotoxin in the house dust of those with the highest degree of immunoglobulin E (IgE) sensitization to environmental allergens [<a href="#rid95">95</a>]. Another study showed that lipoteichoic acid, another component of bacterial cell walls, interacts with TLR2 to downregulate the receptor of IgE (Fc-epsilon-RI) on mast cells [<a href="#rid96">96</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, a different model showed that activation of TLR4 on the surface of pulmonary epithelial cells seemed to promote the development of allergic airway responses and asthma [<a href="#rid97">97</a>]. In a mouse model, naturally occurring combinations of dust mite allergens and LPS were found to trigger epithelial cells through TLR4, leading to eosinophil recruitment and the production of the T helper type 2 (Th2) cytokines, interleukin-5 (IL-5) and interleukin-13 (IL-13) [<a href="#rid97">97</a>]. Simultaneous inhalation of a TLR4 antagonist completely eliminated the effect. However, the dose of the TLR agonist also plays a role. In another study, low doses of endotoxin acting on TLR4 were observed to enhance Th2 inflammation in a mouse asthma model, whereas high doses induced a T helper type 1 (Th1) response [<a href="#rid98">98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The importance of early exposure to a rich, diverse microbiota in the prevention of atopy is an active area of research. Microbial components (endotoxin) provide robust activation of TLRs, which shape immune responses [<a href="#rid99">99</a>]. Loss of microbiota diversity, on the other hand, may predispose to the development of atopy and asthma. Microbiome diversity can be influenced by infections and the use of antibiotics [<a href="#rid100">100,101</a>]. Mouse models suggest that TLR activation of CD103+ dendritic cells in the gut may play an important role in inducing development of T regulatory cells, leading to induction of tolerance [<a href="#rid102">102</a>]. Furthermore, increased expression of TLR2 and TLR4 on T regulatory cells may be associated with augmented suppressive functions [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of TLR2, TLR4, and TLR9 polymorphisms found relatively minor effects on asthma risk with the possible exception of the TLR2 Arg753Gln alteration, which may have a significant association with asthma risk [<a href="#rid104">104</a>].</p><p></p><p>Thus, activation of innate immune responses through TLRs appears to have critical impact on the early stages of allergic disease, although the nature of this influence requires further study.</p><p class="headingAnchor" id="H26"><span class="h1">TLR-BASED THERAPIES</span><span class="headingEndMark"> — </span>There are several new therapies in use or development that utilize emerging knowledge of TLR biology.</p><p class="headingAnchor" id="H27"><span class="h2">TLR7 agonists</span><span class="headingEndMark"> — </span>TLR7 agonists have been found to be clinically useful in slowing the growth of malignancies and inhibiting viral replication. However, the precise mechanism of action of these agents remains unknown.</p><p class="headingAnchor" id="H28"><span class="h3">Imiquimod</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">Imiquimod</a> is a synthetic agonist of TLR7 that has been proven very effective as monotherapy for basal cell carcinoma when applied topically. It is also used in the treatment of actinic keratoses and genital warts. (See  <a class="medical medical_review" href="/z/d/html/5458.html" rel="external">"Condylomata acuminata (anogenital warts): Treatment of vulvar and vaginal warts", section on 'Imiquimod'</a> and  <a class="medical medical_review" href="/z/d/html/5338.html" rel="external">"Treatment and prognosis of basal cell carcinoma at low risk of recurrence"</a> and  <a class="medical medical_review" href="/z/d/html/5336.html" rel="external">"Treatment of actinic keratosis"</a>.)  </p><p class="headingAnchor" id="H29"><span class="h3">Isatoribine</span><span class="headingEndMark"> — </span>Isatoribine is another synthetic TLR7 agonist. In 12 adults with chronic hepatitis C infection who were otherwise untreated, seven daily injections of isatoribine reduced blood viral load measured by polymerase chain reaction [<a href="#rid105">105</a>]. The therapy was well-tolerated, although the antiviral effect was modest.</p><p class="headingAnchor" id="H30"><span class="h2">TLR9 and CpG DNA</span><span class="headingEndMark"> — </span>Coadministration of oligodeoxynucleotides (ODNs) containing cytosine guanine dinucleotide (CpG) motifs during immunization enhances T helper type 1 (Th1) immune responses in animal models [<a href="#rid106">106</a>]. These ODNs mimic bacterial DNA sequences and interact with TLR9. (See <a class="local">'Specific TLRs'</a> above.)</p><p>ODNs are also being studied in human trials. Subcutaneous injection of ODNs alone into healthy volunteers leads to readily measurable increases of serum Th1 type cytokine levels (interleukin-12 [IL-12], interferon-alpha [IFN-alpha]), as well as cytokines generally associated with T helper type 2 (Th2) activation (interleukin-6 [IL-6]) [<a href="#rid107">107</a>].</p><p class="headingAnchor" id="H31"><span class="h3">Vaccination</span><span class="headingEndMark"> — </span>In a study of an ODN added to a hepatitis B vaccine (Engerix-B), recipients of the vaccine with added ODN had significantly faster and higher hepatitis B surface antibody responses in comparison with controls who received the vaccine alone [<a href="#rid108">108</a>]. The recipients of the vaccine with ODN also had a significantly higher rate of adverse reactions, although these were mostly mild to moderate in severity. TLR4 agonists are used in several vaccines, including those against cervical cancer, shingles, and hepatitis B (brand names Cervarix, Shingrix, and Fendrix, respectively) [<a href="#rid109">109</a>]. During the SARS-CoV-2 pandemic, highly effective TLR-activating mRNA vaccines against COVID-19 were developed, demonstrating the potential of pattern recognition receptors as adjuvants. (see  <a class="medical medical_review" href="/z/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults"</a> and  <a class="medical medical_review" href="/z/d/html/101483.html" rel="external">"Hepatitis B virus immunization in infants, children, and adolescents"</a>).</p><p>Newborns and infants are more susceptible to infection, particularly by intracellular pathogens. The development of vaccines utilizing TLR agonists within nanoparticles shows promise in inducing adult-like immune responses in neonates, perhaps enhancing immune protection in this vulnerable population [<a href="#rid110">110</a>].</p><p class="headingAnchor" id="H32"><span class="h3">Cancer therapy</span><span class="headingEndMark"> — </span>CpG ODN are also being studied as agents for cancer therapy. These have been administered in combination with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in a phase 1 trial in 20 patients with relapsed non-Hodgkin lymphoma [<a href="#rid111">111</a>]. The therapy was well tolerated. Increased levels of mRNA for interferon-inducible genes were detected in the peripheral blood mononuclear cells of patients after receiving ODN.</p><p>ODN have also been studied as an adjuvant for a cancer vaccine. Patients with newly diagnosed metastatic colon cancer and elevated serum carcinoembryonic antigen (CEA) levels were given a regimen combining chemotherapy with a cancer vaccine [<a href="#rid112">112</a>]. The vaccine was comprised of a CEA-derived peptide with one of three adjuvants: ODN, granulocyte colony-stimulating factor (G-CSF), or autologous dendritic cells. The vaccines were of apparently equivalent immunogenicity. Eight of 17 (47 percent) patients developed cytotoxic anti-CEA T cell responses, despite having received concomitant immunosuppressive chemotherapy.</p><p>Loading of the TLR7 agonist resiquimod onto nanoparticles shows promise in enhancing the immune response against tumor cells. Subcutaneous injection of resiquimod loaded nanoparticles into tumor-bearing mice have been shown to accumulate into tumor-draining lymph nodes where they can activate dendritic cells, leading to a cytotoxic T cell response [<a href="#rid113">113</a>].</p><p class="headingAnchor" id="H33"><span class="h3">Allergen immunotherapy</span><span class="headingEndMark"> — </span>Coupling of an ODN to an allergen has been evaluated as possible immunotherapy for atopic disease [<a href="#rid114">114-116</a>]. This strategy uses TLR9 as a potent inducer of Th1 T cell responses, thereby reducing Th2 or atopic responses:</p><p class="bulletIndent1"><span class="glyph">●</span>In one randomized trial, 19 adults allergic to ragweed received subcutaneous injections of a major ragweed pollen allergen (Amb a 1) coupled to an ODN [<a href="#rid114">114</a>]. The injections were well tolerated, and the investigators demonstrated in vitro a shift of the peripheral blood T cell cytokine secretion profile from Th2 ("allergic") to Th1 ("nonallergic").</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In two separate double-blind, placebo-controlled trials of 57 adults [<a href="#rid115">115</a>] and 25 adults [<a href="#rid116">116</a>] with ragweed allergy, subjects were randomly assigned to treatment using similar preparations of ragweed pollen allergen coupled to ODN, given by subcutaneous injection. In both trials, patients reported clinical benefits for up to two successive ragweed pollen seasons following a course of only six injections.</p><p></p><p class="headingAnchor" id="H34"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Toll-like receptors (TLRs) belong to a class of molecules known as pattern recognition receptors (PRRs). The ligands for these receptors are components of pathogenic microbes called pathogen-associated molecular patterns (PAMPs). TLRs are part of the innate immune system, although they also modulate mechanisms that impact the development of adaptive immune responses. (See <a class="local">'Role in innate immunity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TLRs are expressed on leukocytes and various solid tissue cells. The cellular localization of TLRs varies. TLR2/1, TLR2/6, TLR4, TLR5, TLR10, and TLR11 are localized to cell surfaces, whereas TLR3, TLR7, TLR8, and TLR9 are localized within endosomes. (See <a class="local">'Cellular and tissue distribution'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The structure of all of the TLRs is similar. Receptor structure, organization, ligands, and signaling are summarized in the table  (<a class="graphic graphic_table graphicRef61291" href="/z/d/graphic/61291.html" rel="external">table 1</a>) and figure  (<a class="graphic graphic_figure graphicRef57602" href="/z/d/graphic/57602.html" rel="external">figure 1</a>). The final common pathway for TLR signaling involves transcription factors that regulate a multitude of genes, including those encoding important proinflammatory cytokines and type 1 interferons. (See <a class="local">'Structure and function of TLRs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Defects in proximal signaling molecules within TLR signaling pathways, including myeloid differentiation primary response protein 88 (MyD88) and interleukin-1 receptor-associated kinase 4 (IRAK4), have been implicated in primary immunodeficiency to a narrow spectrum of microbes, resulting in susceptibility to pyogenic bacterial infections. (See <a class="local">'MyD88/IRAK4/IRAK1 deficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>UNC93B1 (UNC93 homolog B1), TLR3, toll/interleukin-1 (IL-1) receptor (TIR) domain-containing adapter-inducing interferon-beta (IFN-beta) (TRIF), tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3), and tank-binding kinase 1 (TBK1) mutations have been identified in patients with selective susceptibility to herpes simplex virus type 1 (HSV-1) encephalitis, severe influenza pneumonia and encephalopathy, and severe coronavirus disease 2019 (COVID-19). (See <a class="local">'UNC93B1 deficiency, TLR3 mutations, TRIF deficiency, TRAF3 deficiency, and TBK1 deficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Defects in more distal components of TLR signaling pathways (ie, nuclear factor [NF]-kappa-B essential modulator [NEMO], I-kappa-B-alpha, heme-oxidized IRP2 ubiquitin ligase-1 [HOIL-1], and HOIL-1 interacting protein [<em>HOIP</em>]) are associated with broader infectious susceptibilities (bacteria, mycobacteria, viruses, fungi, opportunistic organisms). Dedicator of cytokinesis 8 (DOCK8) deficiency impairs multiple cellular functions in a variety of cells types, leading to a combined immunodeficiency. (See <a class="local">'TLR signaling defects in primary immunodeficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TLR-based therapies in development or in use include the TLR7 agonists <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> and isatoribine. In addition, oligodeoxynucleotides (ODN) containing cytosine guanine dinucleotide (CpG) motifs, presumably through binding to TLR9, have been found to augment T helper type 1 (Th1) immune responses and have been applied to vaccination, cancer therapy, and immunotherapy for allergic disease. (See <a class="local">'TLR-based therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of TLR agonists in several vaccines in clinical use demonstrates their utility in the development of highly effective vaccines in the prevention human diseases. (See <a class="local">'Vaccination'</a> above.)</p><p></p><p class="headingAnchor" id="H1786384535"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Francisco A Bonilla, MD, PhD, who contributed to earlier versions of this topic review.</p><p>The UpToDate editorial staff also acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schnare M, Rollinghoff M, Qureshi S. Toll-like receptors: sentinels of host defence against bacterial infection. Int Arch Allergy Immunol 2006; 139:75.</a></li><li><a class="nounderline abstract_t">Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009; 388:621.</a></li><li><a class="nounderline abstract_t">Gazzinelli RT, Denkers EY. Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism. Nat Rev Immunol 2006; 6:895.</a></li><li><a class="nounderline abstract_t">Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006; 117:979.</a></li><li><a class="nounderline abstract_t">Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168:554.</a></li><li><a class="nounderline abstract_t">Gewirtz AT, Navas TA, Lyons S, et al. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001; 167:1882.</a></li><li><a class="nounderline abstract_t">Brinkmann MM, Spooner E, Hoebe K, et al. The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J Cell Biol 2007; 177:265.</a></li><li><a class="nounderline abstract_t">Beutler BA. TLRs and innate immunity. Blood 2009; 113:1399.</a></li><li><a class="nounderline abstract_t">Shinohara ML, Lu L, Bu J, et al. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol 2006; 7:498.</a></li><li><a class="nounderline abstract_t">Schoenemeyer A, Barnes BJ, Mancl ME, et al. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem 2005; 280:17005.</a></li><li><a class="nounderline abstract_t">Yoshimura A, Ohishi HM, Aki D, Hanada T. Regulation of TLR signaling and inflammation by SOCS family proteins. J Leukoc Biol 2004; 75:422.</a></li><li><a class="nounderline abstract_t">Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16:3.</a></li><li><a class="nounderline abstract_t">Ignacio A, Morales CI, Câmara NO, Almeida RR. Innate Sensing of the Gut Microbiota: Modulation of Inflammatory and Autoimmune Diseases. Front Immunol 2016; 7:54.</a></li><li><a class="nounderline abstract_t">Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499.</a></li><li><a class="nounderline abstract_t">Kawai T, Akira S. TLR signaling. Cell Death Differ 2006; 13:816.</a></li><li><a class="nounderline abstract_t">Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5:446.</a></li><li><a class="nounderline abstract_t">Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17:1.</a></li><li><a class="nounderline abstract_t">Ozinsky A, Underhill DM, Fontenot JD, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A 2000; 97:13766.</a></li><li><a class="nounderline abstract_t">Buwitt-Beckmann U, Heine H, Wiesmüller KH, et al. TLR1- and TLR6-independent recognition of bacterial lipopeptides. J Biol Chem 2006; 281:9049.</a></li><li><a class="nounderline abstract_t">Omueti KO, Beyer JM, Johnson CM, et al. Domain exchange between human toll-like receptors 1 and 6 reveals a region required for lipopeptide discrimination. J Biol Chem 2005; 280:36616.</a></li><li><a class="nounderline abstract_t">Massari P, Henneke P, Ho Y, et al. Cutting edge: Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent. J Immunol 2002; 168:1533.</a></li><li><a class="nounderline abstract_t">LeBouder E, Rey-Nores JE, Rushmere NK, et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 2003; 171:6680.</a></li><li><a class="nounderline abstract_t">Schröder M, Bowie AG. TLR3 in antiviral immunity: key player or bystander? Trends Immunol 2005; 26:462.</a></li><li><a class="nounderline abstract_t">Tanabe M, Kurita-Taniguchi M, Takeuchi K, et al. Mechanism of up-regulation of human Toll-like receptor 3 secondary to infection of measles virus-attenuated strains. Biochem Biophys Res Commun 2003; 311:39.</a></li><li><a class="nounderline abstract_t">Pisegna S, Pirozzi G, Piccoli M, et al. p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells. Blood 2004; 104:4157.</a></li><li><a class="nounderline abstract_t">Muroi M, Tanamoto K. Structural regions of MD-2 that determine the agonist-antagonist activity of lipid IVa. J Biol Chem 2006; 281:5484.</a></li><li><a class="nounderline abstract_t">Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1:398.</a></li><li><a class="nounderline abstract_t">Sasu S, LaVerda D, Qureshi N, et al. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res 2001; 89:244.</a></li><li><a class="nounderline abstract_t">Johnson GB, Brunn GJ, Platt JL. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol 2003; 23:15.</a></li><li><a class="nounderline abstract_t">Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410:1099.</a></li><li><a class="nounderline abstract_t">Heil F, Ahmad-Nejad P, Hemmi H, et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003; 33:2987.</a></li><li><a class="nounderline abstract_t">Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526.</a></li><li><a class="nounderline abstract_t">Lund JM, Alexopoulou L, Sato A, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 2004; 101:5598.</a></li><li><a class="nounderline abstract_t">Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31:3026.</a></li><li><a class="nounderline abstract_t">Hasan U, Chaffois C, Gaillard C, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 2005; 174:2942.</a></li><li><a class="nounderline abstract_t">Oosting M, Cheng SC, Bolscher JM, et al. Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proc Natl Acad Sci U S A 2014; 111:E4478.</a></li><li><a class="nounderline abstract_t">Henrick BM, Yao XD, Zahoor MA, et al. TLR10 Senses HIV-1 Proteins and Significantly Enhances HIV-1 Infection. Front Immunol 2019; 10:482.</a></li><li><a class="nounderline abstract_t">Thoma-Uszynski S, Stenger S, Takeuchi O, et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001; 291:1544.</a></li><li><a class="nounderline abstract_t">Aliprantis AO, Yang RB, Weiss DS, et al. The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J 2000; 19:3325.</a></li><li><a class="nounderline abstract_t">Ayabe T, Ashida T, Kohgo Y, Kono T. The role of Paneth cells and their antimicrobial peptides in innate host defense. Trends Microbiol 2004; 12:394.</a></li><li><a class="nounderline abstract_t">Birchler T, Seibl R, Büchner K, et al. Human Toll-like receptor 2 mediates induction of the antimicrobial peptide human beta-defensin 2 in response to bacterial lipoprotein. Eur J Immunol 2001; 31:3131.</a></li><li><a class="nounderline abstract_t">Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr Opin Immunol 2002; 14:96.</a></li><li><a class="nounderline abstract_t">Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2:675.</a></li><li><a class="nounderline abstract_t">Bowie A, Kiss-Toth E, Symons JA, et al. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci U S A 2000; 97:10162.</a></li><li><a class="nounderline abstract_t">Harte MT, Haga IR, Maloney G, et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 2003; 197:343.</a></li><li><a class="nounderline abstract_t">von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008; 321:691.</a></li><li><a class="nounderline abstract_t">Picard C, von Bernuth H, Ghandil P, et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) 2010; 89:403.</a></li><li><a class="nounderline abstract_t">McDonald DR, Goldman F, Gomez-Duarte OD, et al. Impaired T-cell receptor activation in IL-1 receptor-associated kinase-4-deficient patients. J Allergy Clin Immunol 2010; 126:332.</a></li><li><a class="nounderline abstract_t">Ku CL, Yang K, Bustamante J, et al. Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunol Rev 2005; 203:10.</a></li><li><a class="nounderline abstract_t">Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003; 299:2076.</a></li><li><a class="nounderline abstract_t">Ku CL, von Bernuth H, Picard C, et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 2007; 204:2407.</a></li><li><a class="nounderline abstract_t">Bousfiha A, Picard C, Boisson-Dupuis S, et al. Primary immunodeficiencies of protective immunity to primary infections. Clin Immunol 2010; 135:204.</a></li><li class="breakAll">The Toll-like receptor function assay (#0051589). www.aruplab.com (Accessed on March 31, 2017).</li><li><a class="nounderline abstract_t">Della Mina E, Borghesi A, Zhou H, et al. Inherited human IRAK-1 deficiency selectively impairs TLR signaling in fibroblasts. Proc Natl Acad Sci U S A 2017; 114:E514.</a></li><li><a class="nounderline abstract_t">Zhang SY, Jouanguy E, Ugolini S, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007; 317:1522.</a></li><li><a class="nounderline abstract_t">Casrouge A, Zhang SY, Eidenschenk C, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006; 314:308.</a></li><li><a class="nounderline abstract_t">Jouanguy E, Zhang SY, Chapgier A, et al. Human primary immunodeficiencies of type I interferons. Biochimie 2007; 89:878.</a></li><li><a class="nounderline abstract_t">Zhang SY, Jouanguy E, Sancho-Shimizu V, et al. Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immunol Rev 2007; 220:225.</a></li><li><a class="nounderline abstract_t">Sancho-Shimizu V, Pérez de Diego R, Lorenzo L, et al. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J Clin Invest 2011; 121:4889.</a></li><li><a class="nounderline abstract_t">Pérez de Diego R, Sancho-Shimizu V, Lorenzo L, et al. Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 2010; 33:400.</a></li><li><a class="nounderline abstract_t">Herman M, Ciancanelli M, Ou YH, et al. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J Exp Med 2012; 209:1567.</a></li><li><a class="nounderline abstract_t">Lim HK, Huang SXL, Chen J, et al. Severe influenza pneumonitis in children with inherited TLR3 deficiency. J Exp Med 2019; 216:2038.</a></li><li><a class="nounderline abstract_t">Ciancanelli MJ, Huang SX, Luthra P, et al. Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science 2015; 348:448.</a></li><li><a class="nounderline abstract_t">Hernandez N, Melki I, Jing H, et al. Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency. J Exp Med 2018; 215:2567.</a></li><li><a class="nounderline abstract_t">Hidaka F, Matsuo S, Muta T, et al. A missense mutation of the Toll-like receptor 3 gene in a patient with influenza-associated encephalopathy. Clin Immunol 2006; 119:188.</a></li><li><a class="nounderline abstract_t">Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020; 370.</a></li><li><a class="nounderline abstract_t">Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020; 370.</a></li><li><a class="nounderline abstract_t">Picard C, Casanova JL, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency. Clin Microbiol Rev 2011; 24:490.</a></li><li><a class="nounderline abstract_t">Zhang Q, Davis JC, Lamborn IT, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med 2009; 361:2046.</a></li><li><a class="nounderline abstract_t">Janssen E, Tohme M, Hedayat M, et al. A DOCK8-WIP-WASp complex links T cell receptors to the actin cytoskeleton. J Clin Invest 2016; 126:3837.</a></li><li><a class="nounderline abstract_t">Jabara HH, McDonald DR, Janssen E, et al. DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. Nat Immunol 2012; 13:612.</a></li><li><a class="nounderline abstract_t">Keles S, Jabara HH, Reisli I, et al. Plasmacytoid dendritic cell depletion in DOCK8 deficiency: rescue of severe herpetic infections with IFN-α 2b therapy. J Allergy Clin Immunol 2014; 133:1753.</a></li><li><a class="nounderline abstract_t">Boisson B, Laplantine E, Prando C, et al. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat Immunol 2012; 13:1178.</a></li><li><a class="nounderline abstract_t">Boisson B, Laplantine E, Dobbs K, et al. Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia. J Exp Med 2015; 212:939.</a></li><li><a class="nounderline abstract_t">Borzutzky A, Rauter I, Fried A, et al. Defective TLR9-driven STAT3 activation in B cells of patients with CVID. Clin Immunol 2018; 197:40.</a></li><li><a class="nounderline abstract_t">Yu JE, Knight AK, Radigan L, et al. Toll-like receptor 7 and 9 defects in common variable immunodeficiency. J Allergy Clin Immunol 2009; 124:349.</a></li><li><a class="nounderline abstract_t">Yu JE, Zhang L, Radigan L, et al. TLR-mediated B cell defects and IFN-α in common variable immunodeficiency. J Clin Immunol 2012; 32:50.</a></li><li><a class="nounderline abstract_t">Fliegauf M, Bryant VL, Frede N, et al. Haploinsufficiency of the NF-κB1 Subunit p50 in Common Variable Immunodeficiency. Am J Hum Genet 2015; 97:389.</a></li><li><a class="nounderline abstract_t">Chen K, Coonrod EM, Kumánovics A, et al. Germline mutations in NFKB2 implicate the noncanonical NF-κB pathway in the pathogenesis of common variable immunodeficiency. Am J Hum Genet 2013; 93:812.</a></li><li class="breakAll">Several commercial genetics laboratories offer this test. An example in the United States is Gene Dx.</li><li class="breakAll">Several commercial laboratories offer testing for TLR function. Examples in the United States include ViracorIBT and ARUP.</li><li><a class="nounderline abstract_t">Deering RP, Orange JS. Development of a clinical assay to evaluate toll-like receptor function. Clin Vaccine Immunol 2006; 13:68.</a></li><li><a class="nounderline abstract_t">von Aulock S, Schröder NW, Gueinzius K, et al. Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis 2003; 188:938.</a></li><li><a class="nounderline abstract_t">Bochud PY, Hawn TR, Aderem A. Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J Immunol 2003; 170:3451.</a></li><li><a class="nounderline abstract_t">Schmitt C, Humeny A, Becker CM, et al. Polymorphisms of TLR4: rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles. Clin Chem 2002; 48:1661.</a></li><li><a class="nounderline abstract_t">Plantinga TS, Johnson MD, Scott WK, et al. Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J Infect Dis 2012; 205:934.</a></li><li><a class="nounderline abstract_t">Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359:1766.</a></li><li><a class="nounderline abstract_t">van der Graaf C, Kullberg BJ, Joosten L, et al. Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Cytokine 2005; 30:264.</a></li><li><a class="nounderline abstract_t">Imahara SD, Jelacic S, Junker CE, O'Keefe GE. The TLR4 +896 polymorphism is not associated with lipopolysaccharide hypo-responsiveness in leukocytes. Genes Immun 2005; 6:37.</a></li><li><a class="nounderline abstract_t">Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002; 105:15.</a></li><li><a class="nounderline abstract_t">Michelsen KS, Doherty TM, Shah PK, Arditi M. TLR signaling: an emerging bridge from innate immunity to atherogenesis. J Immunol 2004; 173:5901.</a></li><li><a class="nounderline abstract_t">Kiechl S, Egger G, Mayr M, et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001; 103:1064.</a></li><li><a class="nounderline abstract_t">Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105:1158.</a></li><li><a class="nounderline abstract_t">Walton KA, Hsieh X, Gharavi N, et al. Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J Biol Chem 2003; 278:29661.</a></li><li><a class="nounderline abstract_t">Gereda JE, Leung DY, Thatayatikom A, et al. Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma. Lancet 2000; 355:1680.</a></li><li><a class="nounderline abstract_t">Yoshioka M, Fukuishi N, Iriguchi S, et al. Lipoteichoic acid downregulates FcepsilonRI expression on human mast cells through Toll-like receptor 2. J Allergy Clin Immunol 2007; 120:452.</a></li><li><a class="nounderline abstract_t">Hammad H, Chieppa M, Perros F, et al. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med 2009; 15:410.</a></li><li><a class="nounderline abstract_t">Dong L, Li H, Wang S, Li Y. Different doses of lipopolysaccharides regulate the lung inflammation of asthmatic mice via TLR4 pathway in alveolar macrophages. J Asthma 2009; 46:229.</a></li><li><a class="nounderline abstract_t">Riiser A. The human microbiome, asthma, and allergy. Allergy Asthma Clin Immunol 2015; 11:35.</a></li><li><a class="nounderline abstract_t">Rodríguez JM, Murphy K, Stanton C, et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis 2015; 26:26050.</a></li><li><a class="nounderline abstract_t">Levin AM, Sitarik AR, Havstad SL, et al. Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity. Sci Rep 2016; 6:31775.</a></li><li><a class="nounderline abstract_t">Farache J, Koren I, Milo I, et al. Luminal bacteria recruit CD103+ dendritic cells into the intestinal epithelium to sample bacterial antigens for presentation. Immunity 2013; 38:581.</a></li><li><a class="nounderline abstract_t">Schaub B, Liu J, Höppler S, et al. Impairment of T-regulatory cells in cord blood of atopic mothers. J Allergy Clin Immunol 2008; 121:1491.</a></li><li><a class="nounderline abstract_t">Tizaoui K, Kaabachi W, Hamzaoui K, Hamzaoui A. Association of Single Nucleotide Polymorphisms in Toll-like Receptor Genes With Asthma Risk: A Systematic Review and Meta-analysis. Allergy Asthma Immunol Res 2015; 7:130.</a></li><li><a class="nounderline abstract_t">Horsmans Y, Berg T, Desager JP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005; 42:724.</a></li><li><a class="nounderline abstract_t">Maletto BA, Rópolo AS, Liscovsky MV, et al. CpG oligodeoxinucleotides functions as an effective adjuvant in aged BALB/c mice. Clin Immunol 2005; 117:251.</a></li><li><a class="nounderline abstract_t">Krieg AM, Efler SM, Wittpoth M, et al. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004; 27:460.</a></li><li><a class="nounderline abstract_t">Cooper CL, Davis HL, Morris ML, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004; 24:693.</a></li><li><a class="nounderline abstract_t">Luchner M, Reinke S, Milicic A. TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases. Pharmaceutics 2021; 13.</a></li><li><a class="nounderline abstract_t">Dowling DJ, Scott EA, Scheid A, et al. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses. J Allergy Clin Immunol 2017; 140:1339.</a></li><li><a class="nounderline abstract_t">Friedberg JW, Kim H, McCauley M, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005; 105:489.</a></li><li><a class="nounderline abstract_t">Weihrauch MR, Ansén S, Jurkiewicz E, et al. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res 2005; 11:5993.</a></li><li><a class="nounderline abstract_t">Mottas I, Bekdemir A, Cereghetti A, et al. Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation. Biomaterials 2019; 190-191:111.</a></li><li><a class="nounderline abstract_t">Simons FE, Shikishima Y, Van Nest G, et al. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004; 113:1144.</a></li><li><a class="nounderline abstract_t">Tulic MK, Fiset PO, Christodoulopoulos P, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004; 113:235.</a></li><li><a class="nounderline abstract_t">Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355:1445.</a></li></ol></div><div id="topicVersionRevision">Topic 3985 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16319494" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Toll-like receptors: sentinels of host defence against bacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19686699" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Toll-like receptors and innate immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17110955" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16675322" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Toll-like receptor function and signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11777946" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11489966" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17452530" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757776" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : TLRs and innate immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16604075" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15695821" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14726494" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Regulation of TLR signaling and inflammation by SOCS family proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14751757" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : TLR signaling pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26925061" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Innate Sensing of the Gut Microbiota: Modulation of Inflammatory and Autoimmune Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15229469" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Toll-like receptor signalling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16410796" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : TLR signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15928677" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Negative regulation of toll-like receptor-mediated immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15585605" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Toll-like receptors in innate immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095740" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16455646" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : TLR1- and TLR6-independent recognition of bacterial lipopeptides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129684" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Domain exchange between human toll-like receptors 1 and 6 reveals a region required for lipopeptide discrimination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11823477" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cutting edge: Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14662871" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16027039" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : TLR3 in antiviral immunity: key player or bystander?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14575692" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mechanism of up-regulation of human Toll-like receptor 3 secondary to infection of measles virus-attenuated strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15315972" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16407172" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Structural regions of MD-2 that determine the agonist-antagonist activity of lipid IVa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11062499" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11485974" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12906258" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Activation of mammalian Toll-like receptors by endogenous agonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11323673" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14579267" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14976262" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15034168" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Recognition of single-stranded RNA viruses by Toll-like receptor 7.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11592079" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728506" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25288745" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Human TLR10 is an anti-inflammatory pattern-recognition receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30930906" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : TLR10 Senses HIV-1 Proteins and Significantly Enhances HIV-1 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11222859" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Induction of direct antimicrobial activity through mammalian toll-like receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10880445" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The apoptotic signaling pathway activated by Toll-like receptor-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15276616" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The role of Paneth cells and their antimicrobial peptides in innate host defense.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11745329" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Human Toll-like receptor 2 mediates induction of the antimicrobial peptide human beta-defensin 2 in response to bacterial lipoprotein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11790538" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Defensins of vertebrate animals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477402" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Toll-like receptors: critical proteins linking innate and acquired immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10920188" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12566418" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18669862" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pyogenic bacterial infections in humans with MyD88 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21057262" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20621347" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Impaired T-cell receptor activation in IL-1 receptor-associated kinase-4-deficient patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15661018" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Inherited disorders of human Toll-like receptor signaling: immunological implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637671" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pyogenic bacterial infections in humans with IRAK-4 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17893200" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20236864" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Primary immunodeficiencies of protective immunity to primary infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20236864" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Primary immunodeficiencies of protective immunity to primary infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28069966" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Inherited human IRAK-1 deficiency selectively impairs TLR signaling in fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17872438" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : TLR3 deficiency in patients with herpes simplex encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16973841" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Herpes simplex virus encephalitis in human UNC-93B deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17561326" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Human primary immunodeficiencies of type I interferons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17979850" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22105173" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20832341" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851595" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31217193" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Severe influenza pneumonitis in children with inherited TLR3 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25814066" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30143481" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16517210" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A missense mutation of the Toll-like receptor 3 gene in a patient with influenza-associated encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32972995" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32972996" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Autoantibodies against type I IFNs in patients with life-threatening COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21734245" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBαdeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19776401" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Combined immunodeficiency associated with DOCK8 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27599296" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A DOCK8-WIP-WASp complex links T cell receptors to the actin cytoskeleton.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22581261" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24767873" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Plasmacytoid dendritic cell depletion in DOCK8 deficiency: rescue of severe herpetic infections with IFN-α2b therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23104095" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26008899" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30145329" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Defective TLR9-driven STAT3 activation in B cells of patients with CVID.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19592080" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Toll-like receptor 7 and 9 defects in common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22048980" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : TLR-mediated B cell defects and IFN-αin common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26279205" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Haploinsufficiency of the NF-κB1 Subunit p50 in Common Variable Immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24140114" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Germline mutations in NFKB2 implicate the noncanonical NF-κB pathway in the pathogenesis of common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24140114" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Germline mutations in NFKB2 implicate the noncanonical NF-κB pathway in the pathogenesis of common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24140114" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Germline mutations in NFKB2 implicate the noncanonical NF-κB pathway in the pathogenesis of common variable immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16426002" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Development of a clinical assay to evaluate toll-like receptor function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12964127" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12646604" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12324481" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Polymorphisms of TLR4: rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22301633" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Toll-like receptor 1 polymorphisms increase susceptibility to candidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18946062" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15927851" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15565173" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The TLR4 +896 polymorphism is not associated with lipopolysaccharide hypo-responsiveness in leukocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11772870" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Impact of infectious burden on extent and long-term prognosis of atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15528321" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : TLR signaling: an emerging bridge from innate immunity to atherogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11222467" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11889007" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12777373" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10905243" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17481719" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Lipoteichoic acid downregulates FcepsilonRI expression on human mast cells through Toll-like receptor 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19330007" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19373628" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Different doses of lipopolysaccharides regulate the lung inflammation of asthmatic mice via TLR4 pathway in alveolar macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26664362" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The human microbiome, asthma, and allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25651996" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The composition of the gut microbiota throughout life, with an emphasis on early life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27558272" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23395676" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Luminal bacteria recruit CD103+ dendritic cells into the intestinal epithelium to sample bacterial antigens for presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18539197" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Impairment of T-regulatory cells in cord blood of atopic mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25729620" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Association of Single Nucleotide Polymorphisms in Toll-like Receptor Genes With Asthma Risk: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116638" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16182607" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : CpG oligodeoxinucleotides functions as an effective adjuvant in aged BALB/c mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15534490" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15622454" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33499143" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28343701" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15358617" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16115944" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415018" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15208597" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767435" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17021320" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
